Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pfizer Berobenatide Side Effects Compare to Wegovy in Phase 2b Trial

The company said monthly dosing kept patients losing weight, with nausea at 38% and vomiting at 23% in the Phase 2b study.

Summary by Quartz
Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly shot

3 Articles

BenzingaBenzinga
Center

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study - Pfizer (NYSE:PFE)

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

·New York, United States
Read Full Article
QuartzQuartz
Center

Pfizer berobenatide side effects compare to Wegovy in Phase 2b trial

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly shot

·New York, United States
Read Full Article
Indian ExpressIndian Express
Lean Left

Pfizer’s new weight-loss shot: Can one injection a month change obesity treatment as we know it?

With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising effectiveness.

·India
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Indian Express broke the news in India on Monday, June 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

FDA icon

FDA

Novo Nordisk icon

Novo Nordisk

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal